These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 29707588)

  • 1. Development of Safe and Non-Self-Immunogenic Mucosal Adjuvant by Recombinant Fusion of Cholera Toxin A1 Subunit with Protein Transduction Domain.
    Shim BS; Cheon IS; Lee E; Park SM; Choi Y; Jung DI; Yang E; Choi JA; Chun JY; Kim JO; Yun CH; Czerkinsky C; Song MK
    J Immunol Res; 2018; 2018():9830701. PubMed ID: 29707588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucosal vaccination of conserved sM2, HA2 and cholera toxin subunit A1 (CTA1) fusion protein with poly gamma-glutamate/chitosan nanoparticles (PC NPs) induces protection against divergent influenza subtypes.
    Chowdhury MYE; Kim TH; Uddin MB; Kim JH; Hewawaduge CY; Ferdowshi Z; Sung MH; Kim CJ; Lee JS
    Vet Microbiol; 2017 Mar; 201():240-251. PubMed ID: 28284616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intranasal inoculate of influenza virus vaccine against lethal virus challenge.
    Fan X; Su Q; Qiu F; Yi Y; Shen L; Jia Z; Liang P; Zou Y; Bi S
    Vaccine; 2018 Jul; 36(29):4354-4361. PubMed ID: 29880240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel non-toxic combined CTA1-DD and ISCOMS adjuvant vector for effective mucosal immunization against influenza virus.
    Eliasson DG; Helgeby A; Schön K; Nygren C; El-Bakkouri K; Fiers W; Saelens X; Lövgren KB; Nyström I; Lycke NY
    Vaccine; 2011 May; 29(23):3951-61. PubMed ID: 21481325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intranasal Immunization with Influenza Virus-Like Particles Containing Membrane-Anchored Cholera Toxin B or Ricin Toxin B Enhances Adaptive Immune Responses and Protection against an Antigenically Distinct Virus.
    Ji X; Ren Z; Xu N; Meng L; Yu Z; Feng N; Sang X; Li S; Li Y; Wang T; Zhao Y; Wang H; Zheng X; Jin H; Li N; Yang S; Cao J; Liu W; Gao Y; Xia X
    Viruses; 2016 Apr; 8(4):115. PubMed ID: 27110810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvanticity of the cholera toxin A1-based gene fusion protein, CTA1-DD, is critically dependent on the ADP-ribosyltransferase and Ig-binding activity.
    Agren LC; Ekman L; Löwenadler B; Nedrud JG; Lycke NY
    J Immunol; 1999 Feb; 162(4):2432-40. PubMed ID: 9973526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine.
    Eliasson DG; El Bakkouri K; Schön K; Ramne A; Festjens E; Löwenadler B; Fiers W; Saelens X; Lycke N
    Vaccine; 2008 Feb; 26(9):1243-52. PubMed ID: 18243429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel concept in mucosal adjuvanticity: the CTA1-DD adjuvant is a B cell-targeted fusion protein that incorporates the enzymatically active cholera toxin A1 subunit.
    Agren L; Löwenadler B; Lycke N
    Immunol Cell Biol; 1998 Jun; 76(3):280-7. PubMed ID: 9682972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein transduction domain-mediated influenza NP subunit vaccine generates a potent immune response and protection against influenza virus in mice.
    Yin Y; Li B; Zhou L; Luo J; Liu X; Wang S; Lu Q; Tan W; Chen Z
    Emerg Microbes Infect; 2020 Dec; 9(1):1933-1942. PubMed ID: 32811334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit.
    Agren LC; Ekman L; Löwenadler B; Lycke NY
    J Immunol; 1997 Apr; 158(8):3936-46. PubMed ID: 9103464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutants of cholera toxin as an effective and safe adjuvant for nasal influenza vaccine.
    Hagiwara Y; Komase K; Chen Z; Matsuo K; Suzuki Y; Aizawa C; Kurata T; Tamura S
    Vaccine; 1999 Jul; 17(22):2918-26. PubMed ID: 10438064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In contrast to conventional inactivated influenza vaccines, 4xM2e.HSP70c fusion protein fully protected mice against lethal dose of H1, H3 and H9 influenza A isolates circulating in Iran.
    Ebrahimi SM; Dabaghian M; Tebianian M; Jazi MH
    Virology; 2012 Aug; 430(1):63-72. PubMed ID: 22595444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A vaccine combination of lipid nanoparticles and a cholera toxin adjuvant derivative greatly improves lung protection against influenza virus infection.
    Bernasconi V; Norling K; Gribonika I; Ong LC; Burazerovic S; Parveen N; Schön K; Stensson A; Bally M; Larson G; Höök F; Lycke N
    Mucosal Immunol; 2021 Mar; 14(2):523-536. PubMed ID: 32807838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CTA1: Purified and display onto gram-positive enhancer matrix (GEM) particles as mucosal adjuvant.
    Zhang Y; Yu X; Hou L; Chen J; Li P; Qiao X; Zheng Q; Hou J
    Protein Expr Purif; 2018 Jan; 141():19-24. PubMed ID: 28866467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice.
    Lei H; Peng X; Jiao H; Zhao D; Ouyang J
    Microb Cell Fact; 2015 Aug; 14():111. PubMed ID: 26242406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection.
    De Filette M; Ramne A; Birkett A; Lycke N; Löwenadler B; Min Jou W; Saelens X; Fiers W
    Vaccine; 2006 Jan; 24(5):544-51. PubMed ID: 16169634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CTA1-DD-immune stimulating complexes: a novel, rationally designed combined mucosal vaccine adjuvant effective with nanogram doses of antigen.
    Mowat AM; Donachie AM; Jägewall S; Schön K; Löwenadler B; Dalsgaard K; Kaastrup P; Lycke N
    J Immunol; 2001 Sep; 167(6):3398-405. PubMed ID: 11544331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protection against multiple influenza A virus strains induced by candidate recombinant vaccine based on heterologous M2e peptides linked to flagellin.
    Stepanova LA; Kotlyarov RY; Kovaleva AA; Potapchuk MV; Korotkov AV; Sergeeva MV; Kasianenko MA; Kuprianov VV; Ravin NV; Tsybalova LM; Skryabin KG; Kiselev OI
    PLoS One; 2015; 10(3):e0119520. PubMed ID: 25799221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Construction and preclinical evaluation of mmCT, a novel mutant cholera toxin adjuvant that can be efficiently produced in genetically manipulated Vibrio cholerae.
    Lebens M; Terrinoni M; Karlsson SL; Larena M; Gustafsson-Hedberg T; Källgård S; Nygren E; Holmgren J
    Vaccine; 2016 Apr; 34(18):2121-8. PubMed ID: 26973069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.